Ligand Pharmaceuticals (LGND) Change in Intangibles (2018 - 2019)

Ligand Pharmaceuticals (LGND) reported Change in Intangibles of $812.8 million for Q1 2019, up 2585.09% sequentially from -$32.7 million in Q4 2018.

Ligand Pharmaceuticals (LGND) Change in Intangibles (2018 - 2019) Analysis & Trends

Ligand Pharmaceuticals (LGND) has 2 years of Change in Intangibles data on file, last reported at $812.8 million in Q1 2019.

For the quarter ending Q1 2019, Change in Intangibles changed N/A year-over-year to $812.8 million; the trailing twelve-month figure through Dec 2019 stood at $812.8 million (changed N/A YoY), and the FY2019 full-year result was $812.8 million, changed N/A from the prior year.
Change in Intangibles rose to $812.8 million in Q1 2019, from -$32.7 million in the prior quarter.
In the past five years, Change in Intangibles ranged from a high of $812.8 million in Q1 2019 to a low of -$32.7 million in Q4 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Change in Intangibles (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn	-
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn	-
7	Belite Bio	62.72 Bn	62.72 Bn	-	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn	-
9	Revolution Medicines	37.35 Bn	37.35 Bn	-	-
10	Ligand Pharmaceuticals	5.92 Bn	5.14 Bn	48.45 Mn	-

Download Data